Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 12;15(1):61.
doi: 10.1186/s40545-022-00457-5.

Adherence to metformin in adults with type 2 diabetes: a combined method approach

Nadia Farhanah Syafhan  1   2 , Rosemary Donnelly  3 , Roy Harper  3 , Janet Harding  3 , Ciara Mulligan  3 , Anita Hogg  4 , Michael Scott  4 , Glenda Fleming  4 , Claire Scullin  4 , Ahmed F Hawwa  1   5 , Gaoyun Chen  1 , Carole Parsons  1 , James C McElnay  6
Affiliations

Adherence to metformin in adults with type 2 diabetes: a combined method approach

Nadia Farhanah Syafhan et al. J Pharm Policy Pract. .

Abstract

Background: Medication adherence, one of the most important aspects in the process of optimal medicines use, is unfortunately still a major challenge in modern healthcare, and further research is required into how adherence can be assessed and optimised. The aim of this study was to use a combined method approach of self-report and dried blood spot (DBS) sampling coupled with population pharmacokinetic (PopPK) modelling, to assess adherence to metformin in adult patients with type 2 diabetes. Further aims were to assess metformin exposure levels in patients, determine factors associated with non-adherence with prescribed metformin, and to explore the relationship between adherence and therapeutic outcomes.

Methods: A combined method approach was used to evaluate metformin adherence in patients with type 2 diabetes who had been prescribed metformin for a minimum period of 6 months. Patients were recruited from consultant-led diabetic outpatient clinics at three hospitals in Northern Ireland, UK. Data collection involved self-reported questionnaires [Medication Adherence Report Scale (MARS), Beliefs about Medicines Questionnaire and Centre for Epidemiologic Studies Depression Scale], direct measurement of metformin concentration in DBS samples, and researcher-led patient interviews. The DBS sampling approach was coupled with population pharmacokinetic (PopPK) modelling, which took account of patient characteristics, metformin dosage and type of formulation prescribed (immediate or sustained release).

Results: The proportion of patients considered to be adherent to their prescribed metformin, derived from self-reported MARS scores and metformin concentration in DBS samples, was 61.2% (74 out of 121 patients). The majority (n = 103, 85.1%) of recruited patients had metformin exposure levels that fell within the therapeutic range. However, 17 patients (14.1%) had low exposure to metformin and one patient (0.8%) had undetectable metformin level in their blood sample (non-exposure). Metformin self-administration and use of a purchased adherence pill box significantly increased the probability of a patient being classified as adherent based on logistic regression analysis. Both HbA1c and random glucose levels (representing poor glycaemic control) in the present research were, however, not statistically linked to non-adherence to metformin (P > 0.05).

Conclusions: A significant proportion of participating patients were not fully adherent with their therapy. DBS sampling together with the use of a published PopPK model was a useful, novel, direct, objective approach to estimate levels of adherence in adult patients with type 2 diabetes (61.2%).

Keywords: Adherence; Combined method approach; Metformin; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flowchart of patient recruitment
Fig. 2
Fig. 2
Number of patients who sometimes, often, or always engaged in non-adherent behaviours to metformin stated in the MARS questionnaire
Fig. 3
Fig. 3
Level of metformin exposure in recruited patients
Fig. 4
Fig. 4
Comparison of results of metformin adherence classification of adult patients with type 2 diabetes using the different methods of assessment. MARS: medication adherence report scale; DBS: dried blood spot
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Royal Pharmaceutical Society Medicine optimisation: Helping patient to make the most of medicine. 2013. https://www.rpharms.com/promoting-pharmacy-pdfs/mo---evidence-in-practic.... Accessed 26 May 2016
    1. American Diabetes Association (ADA) 6. Glycemic targets: standards of medical care in diabetes—2018. Diabetes Care. 2018;41:S55–S64. doi: 10.2337/dc18-S006. - DOI - PubMed
    1. National Institute for Health and Clinical Excellence. Managing blood glucose in adults with type 2 diabetes. 2019a. https://pathways.nice.org.uk/pathways/type-2-diabetes-in-adults/managing.... Accessed 25 Sep 2019.
    1. Krass I, Schieback P, Dhippayom T. Adherence to diabetes medication: a systematic review. Diabet Med. 2015;32:725–737. doi: 10.1111/dme.12651. - DOI - PubMed
    1. Egede LE, Gebregziabher M, Echols C, Lynch CP. Longitudinal effects of medication nonadherence on glycemic control. Ann Pharmacother. 2014;48:562–570. doi: 10.1177/1060028014526362. - DOI - PubMed